B-MS opens down as profits miss estimates

26 October 2017
bristol_myers_squibb_big

Bristol-Myers Squibb (NYSE: BMY) has posted profits from the latest quarter that missed analysts’ expectations.

The US pharma major did beat Wall Street estimates with its revenue from the third quarter, of $5.25 billion, which was a 7% rise on the same three months of 2016 and above the $5.19 billion that analysts expected.

Earnings for the latest quarter declined to $845 million, or $0.51 per share, from $1.2 billion, or $0.72 per share in the year-earlier period. Adjusted earnings-per-share were $0.75, below the Wall Street estimate of $0.77.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Company News Directory

Companies featured in this story

More ones to watch >


More Features in Pharmaceutical